CI · Cigna Group · Insider Trading

This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 2, 2026.

This option vests in three equal annual installments beginning September 1, 2027.

These restricted shares vest in three equal annual installments beginning September 1, 2027.

Under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation ("Deferral Plan"), directors may elect to defer the payment of the cash and/or common stock portion of their retainers beyond the designated payment date. The phantom stock units described in Table II represent the voluntary deferral of a portion of the reporting person's cash retainer into the hypothetical stock fund under the Deferral Plan. Each phantom stock unit is the economic equivalent of one share of The Cigna Group's common stock and will be settled in cash.

Includes 10.7387 phantom stock units acquired pursuant to a dividend reinvestment feature of the Deferral Plan.

This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2026.

Each phantom stock unit is the economic equivalent of one share of The Cigna Group's common stock and will be settled in cash in accordance with the terms of The Cigna Group Executive Deferred Compensation Plan. The reporting person may transfer his interests in The Cigna Group stock fund into an alternative investment fund.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2026.

This option was granted on February 26, 2020. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2026.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2026.

This option was granted on February 26, 2020. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2026.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2026.

Each phantom stock unit is the economic equivalent of one share of The Cigna Group's common stock and will be settled in cash in accordance with the terms of The Cigna Group Executive Deferred Compensation Plan. The reporting person may transfer his interests in The Cigna Group stock fund into an alternative investment fund.

Each phantom stock unit is the economic equivalent of one share of The Cigna Group's common stock and will be settled in cash in accordance with the terms of The Cigna Group Executive Deferred Compensation Plan. The reporting person may transfer his interests in The Cigna Group stock fund into an alternative investment fund.

This option was granted on February 28, 2018. The option vested in three equal annual installments starting on February 28, 2019.

Represents shares withheld to satisfy tax obligations upon vesting of restricted shares.

Under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation ("Deferral Plan"), directors may elect to defer the payment of the cash and/or common stock portion of their retainers beyond the designated payment date. The phantom stock units described in Table II represent the voluntary deferral of a portion of the reporting person's cash retainer into the hypothetical stock fund under the Deferral Plan. Each phantom stock unit is the economic equivalent of one share of The Cigna Group's common stock and will be settled in cash.

Includes 10.6351 phantom stock units acquired pursuant to a dividend reinvestment feature of the Deferral Plan.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.

This option was granted on February 28, 2018. The option vested in three equal annual installments starting on March 1, 2019.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.

This option was granted on February 28, 2017. The option vested in three equal annual installments starting on March 1, 2018.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.

Represents the weighted average price of the shares sold. The prices actually received ranged from $296.46 to $297.45 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.

Represents the weighted average price of the shares sold. The prices actually received ranged from $287.43 to $288.42 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.

This option was granted on February 28, 2017. The option vested in three equal annual installments starting on March 1, 2018.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.

Represents the weighted average price of the shares sold. The prices actually received ranged from $290.44 to $291.438 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.

This option was granted on February 28, 2018. The option vested in three equal annual installments starting on March 1, 2019.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.

Represents the weighted average price of the shares sold. The prices actually received ranged from $288.435 to $289.41 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.

Represents the weighted average price of the shares sold. The prices actually received ranged from $297.492 to $298.49 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.

Represents the weighted average price of the shares sold. The prices actually received ranged from $294.46 to $295.453 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.

Represents the weighted average price of the shares sold. The prices actually received ranged from $286.43 to $287.425 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.

Represents the weighted average price of the shares sold. The prices actually received ranged from $298.495 to $298.675 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.

Represents the weighted average price of the shares sold. The prices actually received ranged from $291.44 to $292.435 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.

Represents the weighted average price of the shares sold. The prices actually received ranged from $295.46 to $296.45 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.

Represents the weighted average price of the shares sold. The prices actually received ranged from $289.435 to $290.43 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.

Represents the weighted average price of the shares sold. The prices actually received ranged from $293.46 to $294.45 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.

Represents the weighted average price of the shares sold. The prices actually received ranged from $292.44 to $293.435 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.

The reporting person's economic interest in The Cigna Group securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of The Cigna Group stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than The Cigna Group stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for The Cigna Group and pages 51-52 and 118 of The Cigna Group's proxy statement filed with the SEC on March 13, 2026.

The reporting person's economic interest in The Cigna Group securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of The Cigna Group stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than The Cigna Group stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for The Cigna Group and pages 51-52 and 118 of The Cigna Group's proxy statement filed with the SEC on March 13, 2026.

The reporting person's economic interest in The Cigna Group securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of The Cigna Group stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than The Cigna Group stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for The Cigna Group and pages 51-52 and 118 of The Cigna Group's proxy statement filed with the SEC on March 13, 2026.

This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2025.